arrow
R

Roberto Sabbatini

medical oncology
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center

通过在摩德纳肿瘤中心的COMNet平台上对癌症患者记录进行通用数据模型协调,准备真实世界数据

2026-04-090
OAAI
Multidisciplinary therapy managements in endometrial and renal cancer patients treated with pembrolizumab and lenvatinib: a virtuous circle between oncologists and organ specialists

子宫内膜癌和肾癌患者接受帕博利珠单抗和仑伐替尼治疗的多学科治疗管理:肿瘤学家与器官专科医生之间的良性循环

2026-03-110
PRE
A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients

激素敏感型前列腺癌的新型分子特征定义了高风险患者

2025-02-200
OAAI
Niraparib In Patients With No Residual Disease After Primary Surgery: Preliminary Results Of The MITO 40 Study

尼拉帕利在主要手术后无残留疾病患者中的应用:MITO 40研究的初步结果

2025-02-010
PRE
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

在意大利的同情使用计划中接受伊匹单抗和纳武单抗治疗的转移性肾细胞癌患者的伴随药物预后评分: 简要交流

2022-11-043
OAAI
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
2022-09-2311
OAAI
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

验证用于透明细胞肾细胞癌的新型三维 (3D融合) 总体采样方案以克服肿瘤内异质性: Meet-Uro 18研究

2022-04-305
OAAI
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

多西他赛和泼尼松联合或不联合恩扎鲁他胺作为转移性去势抵抗性前列腺癌患者的一线治疗: CHEIRON,一项随机II期试验

2021-09-019
PRE